BiondVax stock: buy or sell?
January 17th, 2020
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel.
Should I buy BiondVax stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, BiondVax stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is BiondVax stock a buy?
Banks and financial institutions post stock ratings everyday.Unfortunately, we couldn't find any rating for BVXV stock for the last 30 days.
BiondVax stock analysis
After sliding a spooky -6.93% yesterday, BiondVax closed today at $10.25 and skyrocketed an astounding 6.00%.
BiondVax skyrocketed 6.00% to $10.25 after reaching all time highs on Tuesday. On Dec 16th, SMA100d and SMA200d crossed up triggering a rise of 23.64%. On December/9 BVXV price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. From a daily perspective, BVXV is in a short term uptrend after plotting its last bottom ($8.55, on Jan 6th) higher than the previous bottom, and its last top ($13.50, on Tuesday) also over the previous top. Now trading in between its last bottom and last top BVXV might consolidate in a plain range, waiting to break out over $13.50 or down under $8.55. On Tuesday, BVXV hit a new all time high, pushing higher than on Monday tops. Check different trading setups that use ATHs as triggers.
BiondVax Pharmaceuticals boosted 5.45% this week and set a new all time high at $13.50. By mid December 2019 BVXV plunged a bloodcurdling -11.57% in just one week. Counting this, it's been 4 climbing weeks in a row, soaring a 34.02%.
BiondVax Pharmaceuticals stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, BVXV might consolidate in a flat-base, waiting to break out over or down under . Since SMA20d and SMA40w crossed up last week, BVXV price climbed $0.67 per share (6.99%). Since early December 2019 when BVXV stock price broke up the SMA40w line, it gained $4.48 (77.64%).
BiondVax stock price history
BiondVax IPO was on May 12th, 2015 at $4.89 per share1. Since then, BVXV stock grew a 109.60%, with an average of 27.40% per year. If you had invested $1,000 in BiondVax stock in 2015, it would worth $1,096.00 today.
1: Adjusted price after possible price splits or reverse-splits.
BiondVax stock historical price chart
BVXV stock reached all-time highs on Tuesday with a price of $13.50.
BiondVax stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not found any price prediction for BiondVax stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareBiondVax presented amazing results for 2018-Q3 . BiondVax rocketed Earnings per Share (EPS) by 1,000.00%, beating analysts of $-0.01. BiondVax posted $-0.11.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , BiondVax Pharmaceuticals annual turnover to M USD from marked in . When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter income marked $-2.25 M with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, BiondVax Pharmaceuticals sales marked a tight move and remained constant a nan%. Looking back to recent quarterly results, BiondVax Pharmaceuticals posted 6 negative quarters in a row.
BiondVax ownershipWhen you are planning to buy shares of a stock, it's worth to review its ownership structure.
BiondVax Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 22.93% of all shares.
In case of BiondVax Pharmaceuticals stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BVXV stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to BiondVax:
|Market cap||$103.1 M|
|Total shares||10.1 M|
|Float shares||5.1 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||22.9%|
|Shares in short selling||0.0%|
|Friday, January 17th, 2020|
|Day range||$9.51 - $10.87|
|Average true range||$1.06|
|50d mov avg||$7.30|
|100d mov avg||$6.54|
|200d mov avg||$6.29|
BiondVax performanceTo better understand BiondVax Pharmaceuticals performance you must becnhmark its gains with other related stocks in same sector or industry. For BiondVax, the benchmark is made against .